Alexion Pharma (ALXN): Could Be The Last Complement Inhibitor Standing - Leerink
- Wall St. set to open flat as earnings season gathers pace
- Alibaba (BABA) Tops Q3 EPS by 17c, Revenues Rise 54%
- DuPont (DD) Tops Q4 EPS by 9c; Sees Merger Closing in First Half
- Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the Street
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) and raised his price target to $211 from $210 on the belief that the company's flagship complement inhibition franchise is likely to remain the dominant, if not only, terminal complement inhibitor on the market.
The analyst's research found that the growing number of manufacturers with competing programs in early stage development face significant technical and market-related challenges to match or surpass Soliris. Given the stage of development, any rival program obtaining approval would enter the market after Alexion’s ALXN1210, and its more convenient dosing schedule will be a significant advantage over most competitors. The analyst views Alexion’s complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases.
The $1 increase is due to an update in the company's financials as they flow through the analyst's average of PE, PEG and DCF.
Shares of Alexion Pharmaceuticals closed at $127.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mercury Computer (MRCY) PT Raised to $30 at Jefferies Following 2Q Report
- GenMark Diagnostics (GNMK) PT Raised to $15 at Needham & Company
- CBS Corp. (CBS): Raising PT On Higher Retransmission Fees - Needham
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!